An Investigator-Sponsored Phase 2 Study of Single Agent Selinexor (KPT-330) in Patients With Relapsed Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Selinexor (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 12 May 2016 Status changed from recruiting to discontinued.
- 20 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 13 Apr 2015 Planned initiation date changed from 1 Jan 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.